<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cannabis Cannabinoid Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Cannabis Cannabinoid Res</journal-id>
<journal-id journal-id-type="publisher-id">can</journal-id>
<journal-title-group>
<journal-title>Cannabis and Cannabinoid Research</journal-title>
</journal-title-group>
<issn pub-type="epub">2378-8763</issn>
<publisher>
<publisher-name>Mary Ann Liebert, Inc., publishers</publisher-name>
<publisher-loc>140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32656342</article-id>
<article-id pub-id-type="pmc">7347041</article-id>
<article-id pub-id-type="publisher-id">10.1089/can.2018.0049</article-id>
<article-id pub-id-type="doi">10.1089/can.2018.0049</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Endocannabinoid System: A New Treatment Target for Obsessive Compulsive Disorder?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kayser</surname>
<given-names>Reilly R.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1,</sup>
</xref>
<xref ref-type="corresp" rid="corr1">
<sup>*</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Snorrason</surname>
<given-names>Ivar</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Haney</surname>
<given-names>Margaret</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Francis S.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Simpson</surname>
<given-names>H. Blair</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><label><sup>1</sup></label>Department of Psychiatry, New York State Psychiatric Institute, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.</aff>
<aff id="aff2"><label><sup>2</sup></label>Department of Psychiatry, Weill Cornell Medical College, New York, New York.</aff>
</contrib-group>
<author-notes>
<corresp id="corr1"><label><sup>*</sup></label>Address correspondence to: Reilly R. Kayser, MD, Department of Psychiatry, New York State Psychiatric Institute, Columbia University Vagelos College of Physicians and Surgeons, 1051 Riverside Drive, 3100 Suite, New York, NY 10032 <email>reilly.kayser@nyspi.columbia.edu</email></corresp>
</author-notes>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>14</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>14</day>
<month>6</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>4</volume>
<issue>2</issue>
<fpage>77</fpage>
<lpage>87</lpage>
<permissions>
<copyright-statement>Copyright 2019, Mary Ann Liebert, Inc., publishers</copyright-statement>
<copyright-year>2019</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="can.2018.0049.pdf" xlink:type="simple"></self-uri>
<abstract>
<title>Abstract</title>
<p><bold>Introduction:</bold> Obsessive-compulsive disorder (OCD) is a disabling illness that is associated with significant functional impairment. Although evidence-based pharmacotherapies exist, currently available medications are ineffective in some patients and may cause intolerable side effects in others. There is an urgent need for new treatments.</p>
<p><bold>Discussion:</bold> A growing body of basic and clinical research has showed that the endocannabinoid system (ECS) plays a role in anxiety, fear, and repetitive behaviors. At the same time, some patients with OCD who smoke cannabis anecdotally report that it relieves their symptoms and mitigates anxiety, and several case reports describe patients whose OCD symptoms improved after they were treated with cannabinoids. Taken together, these findings suggest that the ECS could be a potential target for novel medications for OCD. In this study, we review evidence from both animal and human studies that suggests that the ECS may play a role in OCD and related disorders. We also describe findings from studies in which cannabinoid drugs were shown to impact symptoms of these conditions.</p>
<p><bold>Conclusions:</bold> An emerging body of evidence suggests that the ECS plays a role in OCD symptoms and may be a target for the development of novel medications. Further exploration of this topic through well-designed human trials is warranted.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>anxiety</kwd>
<kwd>cannabinoid</kwd>
<kwd>endocannabinoid system</kwd>
<kwd>OCD</kwd>
<kwd>repetitive behavior</kwd>
</kwd-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="2"></table-count>
<ref-count count="78"></ref-count>
<page-count count="11"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>